Pfizer-BioNTech’s coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 percent, according to real-world evidence published today by the two pharmaceutical companies.
Using data from January 17 to March 6 from Israel’s national vaccination campaign, Pfizer-BioNTech found that prevention against asymptomatic disease also reached 94 percent.
An earlier real-world study using data from between December 20, 2020 and February 1, 2021 had shown effectiveness at preventing symptomatic disease at 94 percent and asymptomatic illness at 92 percent.
“This comprehensive real-world evidence… can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization declared COVID-19 a pandemic,” the two pharmaceutical companies say in a statement.
Israel’s inoculation campaign is the fastest in the world, with some 44 percent of the population already fully vaccinated against the virus. More than five million have received one shot.
It's not (only) about you.
Supporting The Times of Israel isn’t a transaction for an online service, like subscribing to Netflix. The ToI Community is for people like you who care about a common good: ensuring that balanced, responsible coverage of Israel continues to be available to millions across the world, for free.
Sure, we'll remove all ads from your page and you'll unlock access to some excellent Community-only content. But your support gives you something more profound than that: the pride of joining something that really matters.
Join the Times of Israel Community
Join our Community
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
From the Liveblog of
Thursday, March 11, 2021
